Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: androgen receptor antagonists - Medivation

Drug Profile

Research programme: androgen receptor antagonists - Medivation

Alternative Names: MDV 300 series; MDVN 300 series

Latest Information Update: 23 Mar 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at Los Angeles
  • Developer Medivation
  • Class Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 23 Mar 2012 No development reported - Preclinical for Prostate cancer in USA (unspecified route)
  • 29 Jun 2007 Medivation receives clearance from the FDA to commence a phase I/IIa trial of MDV 3100 in hormone-refractory prostate cancer
  • 01 Mar 2007 Preclinical data added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top